This article is more than 5 years old. Information may no longer be current.
OptiMedica sells retina and glaucoma assets to Topcon
Click Here to Manage Email Alerts
SANTA CLARA, Calif. — OptiMedica has signed a definitive agreement to sell its retina and glaucoma assets to Topcon and plans to focus on the laser cataract surgery market, the companies announced in a joint press release.
The purchase, which marks the largest acquisition made thus far by Topcon's medical division, has poised OptiMedica to direct its efforts exclusively to advanced technologies for treating cataract, the release said. OptiMedica expects to launch its proprietary femtosecond phaco system in both U.S. and international markets next year, according to the release.
"This is a very exciting time for OptiMedica, as we transition our highly successful retina and glaucoma franchise to Topcon and devote all of our energy towards revolutionizing cataract surgery," Mark J. Forchette, president and CEO of OptiMedica, said in the release. "Topcon has been an outstanding distribution partner for the PASCAL Photocoagulator in several major markets, so we are confident that they are ideally suited to advancing PASCAL in the global marketplace. With our retina and glaucoma portfolio in the very capable hands of Topcon, OptiMedica will concentrate on delivering the significant innovations that we have developed in laser cataract surgical technology."
Topcon's acquisition underscores the company's commitment to positioning itself as a "total-solutions provider to the eye care practitioner," Hiroshi Fukuzawa, general manager of Topcon's eye care business unit, said in the release. "Given the aging population and continued growth in diabetic and age-related eye disease, the therapeutic laser market continues to be a major opportunity in ophthalmology."
Follow OSNSuperSite.com
on Twitter.